Targeted therapy for small cell lung cancer

doi:10.3760/cma.j.issn.1673,422X.2015.06.014

Abstract

Abstract: argeted agents for small cell lung cancer (SCLC) include inhibitors of angiogenesis, tyrosine kinase inhibitors and signal transduction pathway inhibitors. Bevacizumab, a class of antiangiogenic agent, tends to have no effects on patients. The tyrosine kinase inhibitor, for example sunitinib, may be used as a monotherapy. Signaling inhibitors including Amuvatinib and LDE225 are undergoing phaseⅠand Ⅱ trials. Primary data show that SCLC is not sensitive to targeted therapy, needing more selection, so further studies are requested.

Key words: Lung neoplasms, Carcinoma, small cell, Targeted therapy

Wang Wenxian, Zhang Yiping. Targeted therapy for small cell lung cancer[J]. Journal of International Oncology, 2015, 42(6): 452-454.

References

［1］ Kalemkerian G, Akerley W, Bogner P, et al. Small cell lung cancer［J］. Natl Compr Canc Netw, 2013, 11(1): 78-98. ［2］ Wojcik E, Jakubowicz J, Skotnicki P, et al. IL6 and VEGF in small cell lung cancer patients［J］. Anticancer Res, 2010, 30(5): 1773-1778. ［3］ Horn L, Dahlberg S, Sandler A, et al. Phase Ⅱ study of cisplatin plus etoposide and bevacizumab for previously untreated, extensivestage smallcell lung cancer［J］. J Clin Oncol, 2009, 27(35): 6006-6011. ［4］ Ready N, Dudek A, Pang H, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensivestage smallcell lung cancer: CALGB 30306, a phase Ⅱ study［J］. J Clin Oncol, 2011, 29(33): 4436-4441. ［5］ Spigel D, Townley P, Waterhouse D, et al. Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensivestage smallcell lung cancer: results from the SALUTE trial［J］. J Clin Oncol, 2011, 29(16): 2215-2222. ［6］ Pujol J, Lavole A, Quoix E, et al. Randomized phase Ⅱ/Ⅲ study of bevacizumab in combination with chemotherapy in previously untreated extensive smallcell lung cancer: IFCT0802 trial［J］. J Clin Oncol, 2014, 32(15): 478-478. ［7］ Lu S, Li L, Luo Y, et al. Randomized phase Ⅱ study of recombinant human endostatin in combination with chemotherapy in previously untreated extensivestage smallcell lung cancer (NCT00912392)［J］. J Clin Oncol, 2012, 30(15): 98-102. ［8］ Rachel E, Sanborn J, Patel G, et al. A randomized doubleblind phase Ⅱ trial of platinum plus etoposide with or without cocurrent ZD6474(Z) in patients with previously untreated extensivestage small cell lung cancer: Hoosier Oncology Group LUN06113［J］. J Clin Oncol, 2014, 32(15s): 7506. ［9］ Schneider B, Gadgeel S, Ramnath N, et al. Phase Ⅱ trial of sunitinib maintenance therapy after platinumbased chemotherapy in patients with extensivestage small cell lung cancer［J］. J Thorac Oncol, 2011, 6(6): 1117-1120. ［10］ Han J, Kim H, Lim K, et al. A phase Ⅱ study of sunitinib in patients with relapsed or refractory small cell lung cancer［J］. Lung Cancer, 2013, 79(2): 137-142. ［11］ David R, Spigel A, Spira R, et al. PhaseⅠb of anticancer stem cell antibody OMG59R5 in combination with etoposide and cisplatin in patients with untreated extensivestage small cell lung cancer［J］. J Clin Oncol, 2014, 32(15s): 7601. ［12］ Schmid K, BagoHorvath Z, Berger W, et al. Dual inhibition of egfr and mtor pathways in small cell lung cancer［J］. Br J Cancer, 2010, 103(5): 622-628. ［13］ Tarhini A, Kotsakis A, Gooding W, et al. Phase Ⅱ study of everolimus (RAD001) in previously treated small cell lung cancer［J］. Clin Cancer Res, 2010, 16(23): 5900-5907. ［14］ Besse B, Heist R, Papadmitrakopoulou V, et al. A phaseⅠb doseescalation study of everolimus combined with cisplatin and etoposide as firstline therapy in patients with extensivestage smallcell lung cancer［J］. Ann Oncol, 2014, 25(2): 505-511. ［15］ Tibes R, Fine G, Choy G, et al. A phase Ⅰ firstinhuman doseescalation study of amuvatinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumors［J］. Cancer Chemother Pharmacol, 2013, 71(2): 463-471. ［16］ Mita M, Gordon M, Rosen L, et al. Phase Ⅰb study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors［J］. Cancer Chemother Pharmacol, 2014, 74(1): 195-204. ［17］ Park K, Martelotto L, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer［J］. Nat Med, 2011, 17(11): 1504-1508. ［18］ Maria C, Lee M, Krug A, et al. Phase Ⅰ trial of the hedgehog inhibitor, LDE225, in combination with etoposide and cisplatin for initial treatment of extensive stage small cell lung cancer［J］. J Clin Oncol, 2014, 32(5s): 7602. ［19］ Langer C, Albert L, Kovacs P, et al. Randomized phase Ⅱ study of carboplatin and etoposide with or without obatoclax mesylate in extensivestage small cell lung cancer［J］. Lung Cancer, 2014, 85(3): 420-428. ［20］ Paik P, Rudin C, Pietanza M, et al. A phase Ⅱ study of obatoclax mesylate, a BCL2 antagonist, plus topotecan in relapsed small cell lung cancer［J］. Lung Cancer, 2011, 74(3): 481-485. ［21］ Baggstrom M, Qi Y, Koczywas M, et al. A phase Ⅱ study of AT101 (Gossypol) in chemotherapysensitive recurrent extensivestage small cell lung cancer［J］. J Thorac Oncol, 2011, 6(10): 1757-1760. ［22］ Schelman W, Mohammed T, Traynor A, et al. A phase Ⅰ study of AT101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensivestage small cell lung cancer［J］. Invest New Drugs, 2014, 32(2): 295-302.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[6]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[7]	Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells [J]. Journal of International Oncology, 2023, 50(8): 503-507.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[10]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[11]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[12]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[13]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[14]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(12): 758-762.
[15]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.